Documents in Process

APOEε4 is a genetic risk factor for both Alzheimer's Disease (AD) and dementia with Lewy bodies (DLB). TREM2-dependent microglial activation is considered protective in AD and has been proposed to interact with APOE in this context. [...]

The aim of the present study was to investigate the association between modifiable factors and symptom progression in people with dementia over a period of up to eight years.We used data from a German cohort of community-dwelling individuals who screened positive for dementia in primary care. They underwent comprehensive annual in-home-assessments for up to eight years by specially trained nurses. [...]

The REAL AD study aims to validate the diagnostic and prognostic performance of combining blood-based biomarkers and remote cognitive testing as a screening approach for early Alzheimer's disease (AD), leveraging an existing healthcare infrastructure in Western Sweden. Here, we discuss strategies for recruiting a large and representative cohort, demographics and participant retention during the first study phase, and evaluate the process of implementing innovations enabling a fully remote study design.In April 2024, a recruitment campaign was launched in collaboration with a PR company to recruit at least 3000 participants between 50-80 years from the general population. [...]

A worldwide increase in dementia cases is expected due to demographic changes and the growing elderly population. However, recent studies suggest a declining incidence. [...]

The LIfestyle for BRAin Health (LIBRA) index is a well-validated tool for assessing modifiable dementia risk in midlife and older adults. Less is known about LIBRA in younger adults. [...]

This study assessed costs and cost-associated factors in patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and Alzheimer's Disease (AD) dementia compared to healthy controls.Clinical data, risk factors, healthcare resource use and informal care provision were assessed in the DELCODE study. Costs were calculated from payer and societal perspectives, with multivariate regression analyses identifying cost-associated factors.Societal costs were elevated by 50% for SCD (adjusted mean 7,705€ [95%CI 6,227-9,182€)], 199% for MCI (15,328€ [6,121-24,535€]) and 602% for AD (36,031€ [3,075-68,986€]) compared to controls (5,129€ [3,217-7,042€]). [...]

Good sleep quality is essential for both physiological and mental health. It helps in clearing TAU and beta-amyloid aggregates and consolidating memory, key processes in delaying dementia. [...]

Complement-targeting therapies are pivotal in managing neuromyelitis optica spectrum disorder (NMOSD), calling for a deeper understanding of complement activation across idiopathic inflammatory demyelinating diseases (IIDDs) of the CNS. C4d, a covalently bound complement split product, offers prolonged detectability at activation sites. [...]

A marked evolution in Alzheimer's disease (AD) therapy research is ongoing. In this perspective, we highlight emerging outcomes of tau-targeting approaches with disease-modifying potential evidenced by PET-based slowing of tau accumulation and early signs of cognitive benefit. [...]

Amyloid-positron emission tomography (PET) is pivotal to Alzheimer's management, with the Centiloid standardizing measurements across tracers. AMYPAD trials (Diagnostic and Patient Management Study [DPMS] and Prognostic and Natural History Study [PNHS]) aimed to validate robust quantification in clinical settings. [...]